FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet

uniQure got a message from the FDA this week that the agency is not convinced AMT-130 is doing anything in Huntington's disease — and the path to approval just got a full Phase Three longer.

Moderna is up fourteen percent today. The data that drove it is a forty-nine percent reduction in melanoma recurrence — and the story behind it matters more than the stock move. Let's get into it.

Welcome to The Pharma Closeout for Friday, March sixth. I'm Alex Mercer.

And I'm Maya Patel.

uniQure's program for AMT-130 in Huntington's disease has been one of the more closely watched gene therapy development stories of the last few years. Single-dose administration, Phase One-Two data suggesting measurable slowing of disease progression on both imaging and clinical assessments, and what looked like a credible path toward a BLA filing. This week, the FDA closed that path and pointed toward a longer one. The agency reviewed the existing data package and concluded it is not sufficient to support approval. Their direction to the company: run a full Phase Three randomized controlled trial before re-engaging on a BLA.

A senior FDA official stated on record that the agency is not convinced there is any therapeutic benefit from AMT-130 — and in a disease with zero approved disease-modifying therapies, that language is a departure from the benefit-of-the-doubt framing the field has come to expect. What the FDA is saying here is that single-arm, open-label data in a heterogeneous progressive disease cannot establish benefit without a control arm. That standard is not specific to uniQure — it is the evidentiary threshold for any CNS disease-modifying claim. The field had assumed a program in a disease with no approved alternatives and an urgent unmet need would receive more regulatory latitude on evidentiary standards. Today's communication from the FDA confirms it will not.

uniQure's counterposition is that the Phase One-Two data shows a measurable, meaningful signal on both imaging biomarkers and clinical assessments. The FDA's counterposition is that without a control arm in a progressive disease, you cannot isolate whether any observed stabilization is treatment effect or natural disease variability. Both positions are defensible — but the FDA controls the approval pathway, and right now the agency is asking for a Phase Three.

Here's what I think people are missing in the coverage today. This decision carries implications well beyond uniQure's program specifically. There are gene therapy programs across rare CNS indications — spinal muscular atrophy follow-on work, Friedreich's ataxia programs, early-stage Parkinson's candidates — all watching this regulatory conversation. If the FDA is signaling that randomized, controlled evidence is the floor for CNS gene therapy benefit claims — not a high bar reserved for disputed programs, but the baseline standard — then the financing calculus for early-stage CNS gene therapy changes. Not immediately, but directionally. Investors and companies with exposure to that category will be recalibrating this weekend.

For AMT-130 specifically — a Phase Three in Huntington's disease is not a fast study. Enrollment for a Huntington's Phase Three is slow, and the primary endpoints take years to read out. The timeline for AMT-130 to any potential approval has extended by years, not months. The question now for uniQure is whether they run the Phase Three independently or structure a partnership to share the development risk — and that partnership conversation, if it happens, will be priced against a significantly longer timeline than the market was modeling this morning.

Neither path — independent Phase Three or a partnership — resolves quickly in a disease with slow enrollment and multi-year endpoints. What's confirmed today is that the FDA's evidentiary standard for CNS gene therapy is meaningfully higher than many in the field had assumed going into this interaction, and every rare CNS program watching this conversation is now updating its assumptions on that basis.

Shifting to the deal side — Moderna is up fourteen percent, and the story is in two pieces that together change the company's narrative. First: updated Phase Two-B data for mRNA-4157, their personalized neoantigen cancer vaccine being co-developed with Merck. In melanoma, mRNA-4157 plus Keytruda delivered a forty-nine percent reduction in the risk of recurrence or death versus Keytruda alone. This is not a pivotal readout. The signal has been consistent across multiple interim data cuts, and it is now the clearest public demonstration that mRNA technology can generate a meaningful efficacy signal in a solid tumor indication.

The second piece is the resolution of Moderna's lipid nanoparticle intellectual property dispute. That patent overhang has constrained the company's ability to partner and license freely for two years — every deal conversation Moderna wanted to have carried the background question of whether the LNP IP position would complicate terms. One clinical detail worth flagging on the mRNA-4157 data: that forty-nine percent figure is a recurrence-free survival composite — deaths are included in the endpoint alongside recurrences, not just tumor events. In a Phase Two-B, embedding an OS signal into the primary composite reflects a registration strategy designed for accelerated approval, and Merck co-authors that statistical plan. If the FDA has already reviewed that endpoint design, the Phase Three protocol conversation is further along than the headline data suggests. Taken together, a validated efficacy signal and a cleared IP position: this is the first session in a while where Moderna's story points in one direction.

On M&A — Servier is acquiring Day One Biopharmaceuticals for two-and-a-half billion dollars, twenty-one fifty per share in cash. The asset is Ojemda — Day One's RAF kinase inhibitor for pediatric low-grade glioma, already approved. Let's bring in Marcus Webb on this one.

That's exactly the read. The price reflects what approved orphan oncology assets with pediatric labels command when the acquirer has the runway to hold them long-term.

Two more deals worth flagging. Sanofi has licensed rovadicitinib from Sino Biopharm for up to one-point-five billion dollars, with a hundred and thirty-five million upfront. The differentiation play here is that the compound works through a second pathway in a crowded JAK inhibitor space — in chronic graft-versus-host disease and myelofibrosis, a different mechanism gives Sanofi a clinical positioning story the existing approved agents do not have. And cGvHD is an indication where Sanofi has been deliberately building a franchise position. Lonza also confirmed the divestiture of its Capsules and Health Ingredients business to Lone Star Funds for approximately two-point-three billion Swiss francs — completing the pure-play CDMO pivot they've been telegraphing for over a year. If you have manufacturing dependencies in that business unit, the transition timeline is now confirmed.

The other major data story of this week — Zealand Pharma reported Phase Two results for petrelintide, their amylin analog obesity program developed with Roche. The drug delivered ten-point-seven percent mean body weight reduction at forty-two weeks, with tolerability essentially indistinguishable from placebo. The market's reaction was a thirty-five percent intraday drop — benchmarking that ten-point-seven against the thirteen to twenty percent weight reduction that leading GLP-1 programs have delivered in longer-duration Phase Three data. Zealand's CEO pushed back publicly, arguing that tolerability and long-term patient retention will matter more than peak weight loss as the obesity market matures. That argument is not wrong. It is also not settled by one Phase Two readout. Real-world adherence data over multiple years will determine whether tolerability is a meaningful differentiator in this class.

Also worth noting on the regulatory front — the FDA approved PYLARIFY TruVu today, Lantheus's new formulation of piflufolastat F-eighteen. PYLARIFY has been the standard PSMA PET imaging agent for prostate cancer since its original approval in twenty twenty-one. What changes with TruVu is the manufacturing formulation: it increases batch size by fifty percent and enhances radioactive concentration, enabling wider geographic distribution per production run. Commercial availability is expected in Q4 this year.

The implication here that is easy to miss — PSMA PET imaging is now a standard eligibility criterion or primary endpoint across the active prostate oncology trial pipeline. Wider manufacturing capacity for this specific agent directly affects enrollment feasibility in every one of those trials. TruVu reads as a manufacturing announcement. It functions as a clinical operations story.

Also on today's calendar — Bristol Myers Squibb has a PDUFA date for deucravacitinib in the expanded indication of psoriatic arthritis. If the FDA approves, Sotyktu would become the first TYK2 inhibitor approved in PsA — which is a meaningful competitive positioning story against the JAK inhibitors and biologics that dominate the current treatment landscape. The label differentiation in the immunology space is increasingly important as the PsA market becomes more crowded. And briefly in the global picture: Pfizer's partner Sciwind Biosciences received approval in China for ecnoglutide, a cAMP-biased GLP-1 receptor agonist for obesity achieving fifteen-point-one percent placebo-adjusted weight loss. No US program yet — but if the tolerability profile holds in longer-duration data, it's a different story for the obesity class, which is exactly the variable the whole field is competing on right now. Worth tracking before it arrives in the US clinic.

Looking ahead — the Sotyktu PsA outcome from today's FDA decision will settle over the weekend. Any approval triggers a competitive repositioning conversation immediately across the immunology market. Watch how AbbVie and Pfizer frame their own PsA programs in the days following. On the obesity side, Zealand's CEO made a public argument this week that tolerability beats peak weight loss in the long run. That framing will either gain traction or get buried by the next GLP-1 efficacy readout. The tell will be whether any medical societies or payer analysts pick it up independently.

And Moderna's mRNA-4157 data today sets up a clear next question — when does Phase Three enrollment begin, and does the melanoma signal support accelerating into additional tumor types. A clinical strategy update from the company in the coming weeks will tell us whether today was a genuine inflection point or a strong data cut in an ongoing Phase Two story.

That is your Pharma Closeout for Friday, March sixth. uniQure and the FDA raised the evidentiary floor for CNS gene therapy today. Moderna's oncology story reset in a single session. Servier made a two-and-a-half billion dollar bet on pediatric glioma. And Zealand's petrelintide data launched the debate that will define the obesity class for the next several years — does tolerability beat weight loss? If someone on your team needs to be across this week in pharma, send them the feed.

What a week. Enjoy your weekend — we'll be back Sunday with the Weekend Closeout. See you then.